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Introduction: Photodepletion (PD) is a method to selectively de-
plete alloreactive lymphocytes from the graft to reduce graft versus
host disease (GVHD) in allogeneic stem cell transplantation. We
have previously reported results with PD and shown a low rate of re-
lapse without significant GVHD (Mielke, et al. and McIver, et al.
BBMT2011). In this retrospective analysis, we compared transplants
using photodepleted donor lymphocytes (n 5 24) with a similar co-
hort of T cell depleted (TCD) transplants (n 5 48).
Methods: All subjects received myeloablative conditioning with cy-
clophosphamide (120 mg/kg), fludarabine (125mg/m 2) and TBI (12
Gy, or 4 Gy for age $55). Peripheral blood stem cells were CD34+
selected by the Miltenyi CliniMacs system, with infusion of a target
CD34+ dose of 6 x 106/kg (range 3-10 x 106/kg) and a CD3+ dose of
\5 x 104 /kg. All patients received cyclosporine as the only GVHD
prophylaxis. The PD cohort received 5 x106/kg PD donor lympho-
cytes at day 0 while the TCD cohort received an unmanipulatedDLI
of 5 x106 CD3+/kg on day 90.
Results: Seventy-two patients underwent HLA-identical sibling
transplant. The median age was 43 years (range 16-68), 50% were
males. Transplant indications were AML (29), ALL (17), bipheno-
typic acute leukemia (2), MDS/MPD (15), CML (3), NHL/CLL
(6). Baseline characteristics were similar apart from a greater propor-
tion of high risk patients in the PD cohort (66% vs 50%).
The time to ANC .0.5 x 109/L and the time to complete donor
myeloid chimerism (median, day 14) were similar in both groups,
but PD transplants achieved earlier complete donor T-lymphocyte
engraftment (31 vs 45 days, p 5 0.01). Primary engraftment failure
was seen in 3 patients receiving TCD versus none in the PD cohort.
There were no significant differences in other clinical outcomes. The
cumulative incidence of acute grades II-IV GVHD, III-IV GVHD,
chronic-limited GVHD and chronic-extensive GVHDwere 50% vs
46%, 13% vs 18%, 39% vs 12% and 26% vs 33% respectively, in PD
vs TCD cohorts. With a median follow up of 2.8 years, Kaplan-Me-
ier estimates of overall survival, relapse and nonrelapse mortality
were 44%, 28% and 46% respectively for PD and 49%, 25% and
35% for TCD.
Conclusions: This comparison shows that the addition of 5x106/kg
photodepleted donor lymphocytes at day 0 to a CD34+ selected pe-
ripheral stem cell graft results in superior engraftment, equivalent
low rates of GVHD and equivalent disease control in HLA-matched
sibling transplantation.152
GRANULOCYTE TRANSFUSIONS IN A PATIENT WITH APLASTIC ANEMIA
SUFFERING FROM LIFE-THREATENING FUNGAL INFECTION – GAPPING
FOR HEMATOPOIETIC CELL TRANSPLANTATION
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Background: Acquired aplastic anemia (AA) is the most common
form of bone marrow failure. It is a life-threatening condition ac-
companied by severe infections, including several fungal specious.
Among these, fusarium is emerging pathogen in immunocomprom-
ized patients, particularly those with severe and prolonged neutrope-
nia. Allogeneic hematopoietic cell transplantation (HCT) is the
treatment of choice for AA in patients with matched sibling donor.Patient andMethods:One year old child was diagnosed as suffering
from acquired AA. Due to lack of matched related donor, he received
treatment with cyclosporine-A and anti-thymocytic globulin (ATG).
While being neutropenic, he developed disseminated life-threaten-
ing fusarium fungal infection including positive blood culture, mul-
tiple skin lesions and osteomyelitis. The patient received
amphotericin-B with no clinical improvement and general deteriora-
tion. In order to save the patient’s life and prepare him for future
transplant, he received 12 granulocyte transfusions over a period of
3 months. Granulocytes were harvested from adult volunteers using
granulocyte-colony-stimulating-factor (G-CSF) and dexametha-
sone. Every harvest was divided into 2 doses given every 12 hours.
Results: Skin lesions disappeared, blood cultures became negative
and osteomyelitis resolved during granulocyte transfusions. By that
time a new sibling was born, from whom cord blood was harvested
and HLA examination revealed matched sibling donor. Since the fu-
sarium disseminated infection was controlled the patient was able to
undergo allogeneic HCT using ATG (Fresenius, 5mg/kg/day for 5
days) and cyclophosphamide (50mg/kg/day for 4 days) as condition-
ing regimen. Neutrophil engraftment occurred on day +14 with do-
nor chimerism between 80-90%. No veno-oclusive-disease (VOD)
or graft-versus-host-disease (GVHD) was demonstrated. He is cur-
rently 140 days post transplant alive andwell with no evidence for the
fusarium infection.
Conclusions: Granulocyte transfusions by G-CSF-stimulated do-
nors while waiting HCT should be considered in patients suffering
from life-threatening fungal infections.153
Stemex® IS EXPANDING: PIVOTAL TRIAL NEARS COMPLETION, AND
DEVELOPMENT OF A CRYOPRESERVED PRODUCT IS UNDERWAY
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Cord blood transplantation (CBT) is limited by low number of
TNC and CD34+ cells, influencing the incidence and rate of hema-
topoietic recovery and risk of early transplant-related mortality. Ex
vivo expansion is a strategy to increase the number of progenitor cells
and improve clinical outcomes. Several early stage studies are evalu-
ating the clinical benefit of expansion, mainly in a double CBT con-
figuration. The StemEx trial evaluates the potential contribution
of expansion in a single CBT configuration. StemEx is manufactured
from a portion of a single CBU, originally frozen in 2 separate frac-
tions. CD133+ progenitor cells, purified from the smaller or equal
fraction, are cultured for 21-23 days with cytokines and a copper che-
lator, TEPA, which delays differentiation and promotes expansion of
progenitor cells with engraftment capabilities. A global pivotal reg-
istration study evaluating the safety and efficacy of StemEx in pa-
tients with hematological malignancies following myeloablative
treatment is currently completing recruitment. Safety and efficacy
outcomes of the study will be available in 2012. To date, 82 of 88 Ste-
mEx batches manufactured in 3 centralized GMP facilities, have
been successfully expanded: median fold expansion of TNC,
CD34+ cells and CFU over culture input were 399 (range 52-764),
75 (6-280) and 107 (43-662), respectively. Expansion of only a por-
tion of the CBU resulted in a median 8.4 fold increase (0.8-90.3)
in the number of CD34+ cells infused over the number that would
be infused from the entire CBUwithout expansion. TheCFUpoten-
tial of culture seeded CD133+ cells measured at day-0 of production
indicates the expansion potential of the cryopreserved CB cells. In all
six batches which failed to expand, day-0 CFU was low, while day-
0 CFU of all successfully expanded batches was within specification
ranges. This information, available before patient myeloablation,
strengthens the clinical applicability of StemEx. All StemEx batches
were successfully delivered and infused. We are currently in the last
stages of development of a frozen StemEx product. The added flex-
ibility in the timing of transplantation allows for changes resulting
from patient disease progression or complications. With the chal-
lenges of an ex vivo expanded product being successfully met in
the current registration trial, and the development of a frozen
